Metformin reduces all cause mortality in patients with Type 2 diabetes.
Metformin probably reduces progression to diabetes in patients with
Impaired glucose metablism (fasting or tolerance to load).
Metformin is a relatively safe drug in terms of major side effects.
I have been unable to find any studies of the "routine" prophylactic
use of metformin in non-diabetics post-MI, even those with known
glucose impairment. Relevant end points might be all cause
mortality, progression to diabetes, cardiovascular deaths or events.
Given the prevalence of metabolic syndrome in this population would
such a study be logical, how would it best be accomplished
(Metformin is off patent I'm fairly sure so no big drug
sponsorship... it's more like aspirin)
Julian
|